Use of magnetic resonance imaging contrast agents in the liver and biliary tract

Magnetic Resonance Imaging Clinics of North America

Volumn 20, Issue 4, 2012, Pages 715-737

  LeBedis, Christina ^a   Luna, Antonio ^b,c   Soto, Jorge A ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b Clinica Las Nieves Sercosa   (Spain)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Eovist Primovist; Gadobenate dimeglumine; Gadoxetic acid; Gd DTPA; Hepatobiliary specific MRI contrast; Magnevist; Multihance

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOXETIC ACID; MANGAFODIPIR; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ANATOMICAL VARIATION; BILE DUCT CARCINOMA; BILE DUCT INJURY; CHOLANGIOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIZZINESS; DRUG ELIMINATION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG UPTAKE; HEADACHE; HEART RATE; HOT FLUSH; HUMAN; HYPERTENSION; IMAGE DISPLAY; IMAGE ENHANCEMENT; IMAGE QUALITY; INJECTION SITE PAIN; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER FOCAL NODULAR HYPERPLASIA; LIVER METASTASIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RECOMMENDED DRUG DOSE; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; TASTE DISORDER; VOMITING;

EID: 84867858935     PISSN: 10649689     EISSN: 15579786     Source Type: Journal    
DOI: 10.1016/j.mric.2012.07.006     Document Type: Review

References (64)

1. Carr D.H., Graif M., Niendorf H.P., et al. Gadolinium-DTPA in the assessment of liver tumours by magnetic resonance imaging. Clin Radiol 1986, 37:347-353.
2. Hamm B., Wolf K.J., Felix R. Conventional and rapid MR imaging of the liver with Gd-DTPA. Radiology 1987, 2:313-320.
3. Edelman R.R., Siegel J.B., Singer A., et al. Dynamic MR imaging of the liver with Gd-DTPA: initial clinical results. AJR Am J Roentgenol 1989, 153:1213-1219.
4. Semelka R.C., Helmberger T.K. Contrast agents for MR imaging of the liver. Radiology 2001, 218:27-38.
5. Gandhi S.N., Brown M.A., Wong J.G., et al. MR contrast agents for liver imaging: what, when, how. Radiographics 2006, 26:1621-1636.
6. Seale M.K., Catalano O.A., Saini S., et al. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 2009, 29:1725-1748.
7. Wood M.L., Hardy P.A. Proton relaxation enhancement. J Magn Reson Imaging 1993, 3:149-156.
8. Balci N.C., Semelka R.C. Contrast agents for MR imaging of the liver. Radiol Clin North Am 2005, 43:887-898.
9. Weinmann H.J., Brasch R.C., Press W.R., et al. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 1984, 142:619-624.
10. Shellock F.G., Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 1999, 10:477-484.
11. Niendorf H.P., Alhassan A., Geens V.R., et al. Safety review of gadopentetate dimeglumine: experience after more than five million applications. Invest Radiol 1994, 29(Suppl 2):S179-S182.
12. Wang Y., Alkasab T.K., Narin O., et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011, 260(1):105-111.
13. Wang P.I., Chong S.T., Kielar A.Z., et al. Imaging of pregnant and lactating patients: part 1, evidence-based review and recommendations. AJR Am J Roentgenol 2012, 198:778-784.
14. American College of Radiology (ACR) Website. ACR manual on contrast media, version 7. 2010. Available at: . Accessed May 28, 2012. http://www.acr.org/Quality-Safety/Resources/Contrast-Manual.
15. Reimer P., Schneider G., Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004, 14:559-578.
16. Hussain H.K., Londy F.J., Francis I.R., et al. Hepatic arterial phase MR imaging with automated bolus-detection three-dimensional fast gradient-recalled-echo sequence: comparison with test-bolus method. Radiology 2003, 226:558-566.
17. Bellini M.F., Vasile M., Morel-Precetti S. Currently used non-specific extracellular MR contrast media. Eur Radiol 2003, 13:2688-2698.
18. Rofsky N.M., Earls J.P. Magnafodipir trisodium injection (Mn-DPDP): a contrast agent for abdominal MR imaging. Magn Reson Imaging Clin N Am 1996, 4:73-85.
19. Schneider G., Maas R., Schultze Kool L., et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an individual crossover comparison. Invest Radiol 2003, 38:85-94.
20. Purysko A.S., Remer E.M., Veniero J.C. Focal liver lesion detection and characterization with Gd-EOB-DTPA. Clin Radiol 2011, 66(7):673-684.
21. Tamada T., Ito K., Yamamoto A., et al. Hepatic hemangiomas: evaluation of enhancement patterns at dynamic MRI with gadoxetate disodium. AJR Am J Roentgenol 2011, 196(4):824-830.
22. Doo K.W., Lee C.H., Choi J.W., et al. " Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 2009, 193(6):W490-W496.
23. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factores and incidence estimation. Radiology 2007, 243(1):148-157.
24. Tschirch F.T., Struwe A., Petrowsky H., et al. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 2008, 18:1577-1586.
25. Kanki A., Tamada T., Higaki A., et al. Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis. Magn Reson Imaging 2012, 30:356-360.
26. Huppertz A., Balzer T., Blakeborough A. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004, 230:226-275.
27. Morana G., Grazioli L., Kirchin M.A., et al. Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 2011, 46(4):225-239.
28. Fu G.L., Zee C.S., Yang H.F., et al. Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions. J Comput Assist Tomogr 2012, 36(1):14-19.
29. Grazioli L., Morana G., Kirchin M.A., et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005, 236:166-177.
30. Grazioli L., Bondioni M.P., Haradome H., et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 2012, 262:520-529.
31. Huurman V.A., Schaapherder A.F. Management of ruptured hepatocellular adenoma. Dig Surg 2010, 27:56-60.
32. Bunchorntavakul C., Bahirwani R., Drazek D., et al. Clinial features and natural history of hepatocellular adenomas: the impact of obesity. Aliment Pharmacol Ther 2011, 34(6):664-674.
33. Marin D., Brancatelli G., Federle M.P., et al. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media. Clin Radiol 2008, 63:577-585.
34. Grazioli L., Morana G., Federle M.P., et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001, 221:731-739.
35. Karam A.R., Shankar S., Surapaneni P., et al. Focal nodular hyperplasia: central scar enhancement pattern using gadoxetate disodium. J Magn Reson Imaging 2010, 32(2):341-344.
36. Bioulac-Sage P., Balabaud C., Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg 2010, 27:39-45.
37. Katabathina V.S., Menias C.O., Shanbhogue A.K., et al. Genetics and imaging of hepatocellular adenomas: 2011 update. Radiographics 2011, 31(6):1529-1543.
38. Shanbhogue A.K., Prasad S.R., Takahashi N., et al. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management. Radiology 2011, 258(3):673-693.
39. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142(6):1264-1273.
40. Lee J.M., Choi B.I. Hepatocellular nodules in liver cirrhosis: MR evaluation. Abdom Imaging 2011, 36(3):282-289.
41. Willatt J.M., Hussain H.K., Adusumilli S., et al. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008, 247:311-330.
42. Chanyputhipong J., Low S.C., Chow P.K. Gadoxetate acid-enhanced MR imaging for HCC: a review for clinicians. Int J Hepatol 2011, 2011:489342.
43. Colli A., Fraquelli M., Casazza G., et al. Accuracy of ultrasonography, spiral CT magnetic resonance and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006, 101:513-523.
44. Choi S.H., Lee J.M., Yu N.C., et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 2008, 191(2):529-536.
45. Park Y., Kim S.H., Kim S.H., et al. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience. Korean J Radiol 2010, 11(4):433-440.
46. Kitao A., Matsui O., Yoneda N., et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011, 21(10):2056-2066.
47. Pastor C.M. Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight. Radiology 2010, 257(2):589.
48. Sano K., Ichikawa T., Motosugi U., et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011, 261(3):834-844.
49. Marin D., Di Martino M., Guerrisi A., et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology 2009, 251(1):85-95.
50. Kim T.K., Lee K.H., Jang H.J., et al. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology 2011, 259(3):730-738.
51. Goodwin M.D., Dobson J.E., Sirlin C.B., et al. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics 2011, 31(6):1547-1568.
52. Vigano L., Ferrero A., Lo Tesoriere R., et al. Liver surgery for colorectal mestastases: results after 10 years of follow-up. Long-term sruvivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol 2008, 15(9):2458-2464.
53. Cantwell C.P., Setty B.N., Holalkere N., et al. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI. J Comput Assist Tomogr 2008, 32(5):738-744.
54. Niekel M.C., Bipat S., Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010, 257(3):674-684.
55. Seo H.J., Kim M.J., Lee J.D., et al. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol 2011, 46(9):548-555.
56. Jeon T.Y., Kim S.H., Lee W.J., et al. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma. Abdom Imaging 2010, 35(3):337-345.
57. Irie H., Honda H., Kuroiwa T., et al. Pitfalls in MR cholangiopancreatographic interpretation. Radiographics 2001, 21(1):23-37.
58. Ziessman H.A. Nuclear medicine hepatobiliary imaging. Clin Gastroenterol Hepatol 2010, 8(2):111-116.
59. Gupta R.T., Brady C.M., Lotz J., et al. Dynamic MR imaging of the biliary system using hepatocyte-specific contrast agents. AJR Am J Roentgenol 2010, 195:405-413.
60. Akpinar E., Turkbey B., Karcaaltincaba M., et al. Initial experience on utility of Gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted MR cholangiography in diagnosis of acute cholecystitis. J Magn Reson Imaging 2009, 30:578-585.
61. Krishnan P., Gupta R.T., Boll D.T., et al. Functional evaluation of cystic duct patency with Gd-EOB-DTPA MR imaging: an alternative to hepatobiliary scintigraphy for diagnosis of acute cholecystitis?. Abdom Imaging 2012, 37:457-464.
62. Lee N.K., Kim S., Lee J.W., et al. Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics 2009, 29:1707-1724.
63. Marin D., Bova V., Agnello F., et al. Gadoxetate disodium-enhanced magnetic resonance cholangiography for the noninvasive detection of an active bile leak after laparoscopic cholecystectomy. J Comput Assist Tomogr 2010, 34:213-216.
64. Hoeffel C., Azizi L., Lewin M. Normal and pathologic features of the postoperative biliary tract at 3D MR cholangiopancreatography and MR imaging. Radiographics 2006, 26:1603-1620.